| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | The NICE-Wide Prioritisation Board have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected for evaluation. Decision makers concluded that the clear rationale to not evaluate this product is due to clindamycin already being widely available in the UK in a variety of formulations. Therefore, a NICE evaluation is unlikely to add any further value to the system. |
| ID number | 12127 |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic selection